Philips recognizes that oncology care requires integrated approaches across patient pathways. From diagnosis and staging, to treatment decision, to therapy planning and follow-up, Philips is addressing challenges in cancer care by providing solutions across the entire care delivery pathway. Philips is relentless in its pursuit to help you build best-in-class oncology programs in the ever-changing healthcare landscape. Because today, health knows no bounds and neither should healthcare.

HIFU Prostate Services (HPS) was founded to provide men access to a less invasive treatment option for prostate cancer that has the ability to eliminate cancer and preserve patient quality of life. Our mission is to deliver the highest quality of care, support, and technology to the patient and to the urology community for the treatment of localized prostate cancer. As the industry’s leading HIFU Services provider, HPS continues to evaluate all HIFU technologies for the treatment of prostate cancer to ensure we are offering the safest and most effective HIFU technology on the market.
HPS was founded in 2015 and has a seasoned management team with over 75 years of HIFU experience. HPS is the first, largest, and most experienced HIFU team in the U.S. and has been involved in over 5,000 HIFU procedures, and the first company to reach the 1,500 treatment threshold inside the US. The HPS network currently has over 700 physicians across the U.S., and our physician proctors have experience with over 4,000 HIFU procedures. The company is headquartered in Charlotte, NC and has established partnerships with physicians and urology practices throughout the country. For additional information, visit the website.

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Fueled by the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Alongside its visionary collaborators and in partnership with communities, Exact Sciences unites the best resources to help advance the fight against cancer.

Global leader in therapeutic ultrasound for 40 years, EDAP TMS (NASDAQ: EDAP) develops, manufactures, promotes and distributes minimally invasive medical devices using ultrasound technology. By constantly investing in Research & Development and partnering with internationally renowned medical research institutions, EDAP TMS has developed a strong valuable patent portfolio based on its innovative ultrasound technologies.
EDAP TMS is actively operating worldwide via an extensive network of subsidiaries, corporate offices, and distribution partners. The company is currently marketing two ranges of urology products dedicated to localized prostate cancer and urinary stones. EDAP TMS is also developing its innovative technologies to expand applications beyond urology.
With its complete range of Robotic devices using HIFU (High Intensity Focused Ultrasound), EDAP TMS is the most innovative company in minimally invasive treatment for localized prostate cancer. By combining the latest technologies in imaging and treatment modalities, EDAP TMS introduced the Focal One® as the answer to all requirements for ideal focal therapy of prostate cancer and as a complement to its existing Ablatherm® HIFU device.
Also pioneer and key player in the field of Extracorporeal ShockWave Lithotripsy (ESWL) for urinary stones, EDAP TMS introduced its latest modular lithotripter Sonolith® i-move utilizing the latest generation of shock wave source together with an exclusive unconstrained proprietary ultrasound system (“Visio-Track”) developed by EDAP TMS.

Hitachi Healthcare’s commitment to ultrasound in urology offers a wide range of consoles and specifically designed transducers to meet the needs of every doctor. Recognized for our superior image quality, system reliability and use of cutting edge technology, we remain the standard in the field of ultrasound.

SonaCare Medical is the leading innovator in minimally invasive ablation technology using high intensity focused ultrasound (HIFU). SonaCare Medical’s prostate tissue ablation system, Sonablate®500, incorporates MRI/US image fusion to provide a customized whole gland, hemi-gland, or focal prostate cancer treatment. Exclusive Sonablate fusion software fuses MRI images onto real-time US images in order to facilitate a precision-based ablation treatment plan, which helps to preserve quality of life functions in prostate cancer patients around the world. Sonablate is powered by the company’s pioneering multi-modal console, which allows for surgeons to incorporate additional treatment probes, including a laparoscopic device for soft tissue ablation. Please visit our booth (#2) to learn more about the latest innovations in HIFU therapy.

HealthTronics, Inc., established in 1989 and headquartered in Austin, Texas, provides mobilized medical technologies and services, as well as physician partnership opportunities. With over 500 employees, the company brings advanced laser, cryoablation, lithotripsy technologies and support to healthcare providers throughout the United States. For more information, visit www.healthtronics.com.

Koelis offers an exclusive 3D cartography solution, Trinity®: a fully integrated prostate biopsy system that improves the accuracy of the standard biopsy, enables transperineal biopsy under local anesthetic and provides power, control and management. This is done by their unique 2nd Look Software which helps physicians guide their patients through their arduous prostate cancer journey from diagnosis to treatment.

Biobot Surgical Pte Ltd is a Singapore company incorporated in 2007. We aim to be a global technology leader in minimally-invasive robotic healthcare solutions, especially for prostate cancer management. We use our technology to improve diagnostic and treatment accuracy for patients. We develop state of the art solutions to improve clinical outcome, and hence improve quality of life.

Focal Healthcare is committed to improving the lives of prostate cancer patients and their families through technical innovation. By developing imaging tools that are accurate, efficient and accessible, Focal Healthcare aims to advance prostate cancer diagnosis and management in clinics and hospitals of all sizes.
Based in Toronto, Canada, Focal Healthcare has developed an MRI/TRUS fusion targeted guidance system for prostate biopsy and therapy. By combining information from multiparametric MRI with a semi-robotic arm and user-friendly interface, the Fusion Bx 2.0™ gives urologists the ability to perform targeted transrectal and transperineal prostate biopsies.

BK Medical’s ultrasound solutions provide surgeons with critical information to help make decisions that can impact surgical outcomes. With award-winning systems and unique transducer designs, BK Medical has directly addressed the specialized needs and clinical challenges of urologists worldwide for more than 40 years, offering unsurpassed ultrasound imaging capabilities that enable real-time image guidance with easy-to-use, mobile platforms. BK offers a range of specialized transducers, including the unique patented triplane prostate transducer with simultaneous biplane and end-fire imaging in one transducer.
BK Medical’s bkFusion is a fully integrated prostate fusion biopsy solution with simultaneous display of MRI and real-time ultrasound images on one monitor. bkFusion combines unmatched image quality with a familiar and easy workflow to help make prostate biopsy procedures in either the free-hand transrectal or the transperineal approach as efficient as possible. The urologist maintains control of the entire procedure and can freely adjust ultrasound gain and depth or choose to scan in different planes (transverse, sagittal and end-fire) to better target areas of concern, without the need to resweep or recalibrate during procedures.

Nanospectra Biosciences is a medical device company pioneering the patient-centric use of nanomedicine for selective thermal ablation. The Company’s lead product platform, AuroLase, maximizes treatment efficacy while minimizing side effects associated with surgery, radiation, and traditional focal therapies. It is applicable to a broad range of solid tumor indications. The Company’s technology allows for the selective thermal ablation of solid tumors due to the preferential and passive accumulation of proprietary gold nanoshells in the leaky vasculature of neoplastic tissue. Targeted thermal ablation occurs when optical energy via a low power laser is brought into the immediate proximity of the tumor tissue and is transduced via the optical properties of the gold nanoshells into heat sufficient to kill the cancer cells. The laser energy is sub-ablative in the absence of the nanoshells thus sparing healthy tissue. The inert nanoshells consist of a gold metal shell and a non-conducting silica core and serve as the exogenous absorber of the near infrared laser energy delivered by an optical fiber diffuser. Enrollment and treatment procedures in a 45-patient feasibility study is complete and a 60-patient pivotal study under common FDA IDE approval began in January 2020. The addressable population consists of men with localized disease confirmed as targetable by MRI fusion in men with low/intermediate risk prostate cancer and the therapeutic premise is effective oncologic control with little to no co-morbidities and therefore stable functional outcomes.

Vituro Health’s boutique approach is designed to provide our physicians and patients with a unique experience. Our practices and physicians share a common sensibility and passion to change how prostate cancer is treated and become a center of exceptional medicine offering patients all treatment options. Vituro Health physicians are transforming medicine to a patient-centric system, which in turn, transforms cancer treatment and lives. Our physicians and their administrative teams have been brought together by a common desire to explore new modalities, embrace new technologies and spark innovation for the betterment of humanity. We are the way treatment should be experienced. Vituro Health tailors our partnerships to fit individual practices needs. The Vituro Health network of doctors consistently say they are more than satisfied with the decision to partner with Vituro. Our approach is designed to provide our physicians with an exceptional patient-centric, customizable, non-invasive experience. This synergy transpires through offering the only physician-led, manufacturer-approved training program in the country which includes live proctoring and via Sonalink, peer reviews, medical board protocols, MRI support, webinar series, and access to a partner-only portal. The training program and peer-to-peer support that Vituro doctors receive is the finest in the industry. The burden of introducing a new treatment to cancer patients is eased due to the support available from the Medical Director, Dr. Stephen Scionti and the extensive peer network that have been performing prostate ablation for over 15 years.
As part of our curated services offering, we provide a dedicated patient care team consisting of patient and caregiver ambassadors, insurance reimbursement specialist, and nursing support.

The Focused Ultrasound Foundation is a research, education, and advocacy organization dedicated to improving the lives of millions of patients by accelerating the development and adoption of a revolutionary, noninvasive therapy – focused ultrasound. The technology is in various stages of research and development for more than 130 disease. The Foundation works to clear the path to global adoption by coordinating and funding research, fostering collaboration, and building awareness among patients and professionals. Since its establishment in 2006, the Foundation has become the largest nongovernmental source of funding for focused ultrasound research. For more information, visit www.fusfoundation.org.

Perineologic creates innovative products to increase patient safety and while expanding the ability of the clinicians to treat and manage their patients. Their featured product, PrecisionPoint™ Transperineal Access System, provides exquisite ultrasound guided biopsy of the prostate through the perineum rather than the rectum. This reduces the risk of infection for the patient and provides more precise access to all areas of the prostate to enhance biopsy sampling. Visit our booth to see a demonstration of the PrecisionPoint™ Transperineal Access System and get information for incorporating this pioneering device into your practice.

Wasatch Medical Specialties is the exclusive distributor of Galil Medical’s industry-leading ablation platform for the treatment of prostate cancer. Utilizing a network of highly skilled mobile service providers, we aim to make cryotherapy for the treatment of prostate cancer an accessible and affordable option for doctors and patients anywhere in the US.

SmartBlate is a service company that provides an end to end diagnostic and treatment services for prostate cancer patient with a precise, optimal and practical solution powered by Focalyx Fusion Suite. Its services empower Patients and their Urologists to precisely destroy cancer within the prostate while sparing healthy tissue.
SmartBlate is convenient given that it offers a fast and safe in-office procedure performed in less than ninety (90) minutes, optimal via precise destruction of localized cancer tissue while sparing healthy tissue, and practical as no general anesthesia is required, with minimal post-procedure care.

Profound Medical develops customizable, incision-free therapies which combine real-time Magnetic Resonance (“MR”) imaging, thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. We believe TULSA-PRO® is demonstrating to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (BPH). TULSA-PRO® is CE marked and received 510(k) clearance from the U.S. Food and Drug Administration in August 2019.

UC-CARE is a world leader for Prostate Fusion navigation solutions. For more than 10 years, Navigo & SmartBx, based on advanced missile technology and state of the art signal processing algorithms, have proven to increase detection rate by more than 30%. UC-CARE has led the innovation of Fusion systems with its proprietary technology providing for the most accurate, intuitive, and affordable solutions. UC-CARE is bringing unmatched capabilities to register cancerous tissue location and guide following Active Surveillance & Focal Treatment procedures.
Navigo is the only real-time 3D Fusion navigation system with automatic patient movement compensation and automatic needle detection capabilities, providing unmatched accuracy during biopsy and treatment procedures. Navigo is ultrasound agnostic and has guided thousands of TRUS and TP procedures in office and OR settings. Navigo is widely used by Academic centers and private practices taking advantage of its superior performance and competitive pricing.
SmartBx is the first and only solution for in specimen navigation. SmartBx is a unique biopsy management solution that will safeguard the biopsy specimen and enable accurate cancer localization. Proven over large-scale trials, SmartBx showed significant increase in detection rate! While lowering pathology costs by as much as 50%. SmartBx will enhance any Fusion navigation system and is the only available solution that can truly enable Active Surveillance & Focal Therapy.

Decipher Biosciences is reimagining the use of genomic information to transform and improve cancer patient care.
We are committed to delivering the most accurate tests for determining the true nature of prostate and bladder cancers, enabling each patient to have a treatment plan based on the unique biology of their tumor.